TYRA — Tyra Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1863127 ·
Last close
$19.57
Market Cap
$1.35B
52W High
$40.65
52W Low
$14.84
ADV30
610,723
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -54,885,000 | -51,122,000 | 727,526,000 | 456,016,000 | 34,682,000 |
| Jun 2026 | 0 | — | -49,003,000 | -45,558,000 | 383,362,000 | 73,835,000 | 29,698,000 |
| Mar 2026 | 0 | — | -41,998,000 | -39,305,000 | 412,040,000 | 84,955,000 | 24,465,000 |
| Dec 2025 | 0 | — | -36,516,000 | -33,834,000 | 282,609,000 | 77,387,000 | 23,432,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-119,482,000
Investing CF
$-33,092,000
Financing CF
$546,639,000
CapEx
$-301,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-2.64
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-507,243,000
Inventory
—
Receivables
—
ST Investments
$244,532,000
EBIT TTM
$-182,402,000
Pretax Income TTM
$-169,819,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -132,762,000 | -119,947,000 | 282,609,000 | 23,432,000 | 259,177,000 | -95,142,000 |
| Dec 2024 | 0 | -104,177,000 | -86,481,000 | 363,558,000 | 20,407,000 | 343,151,000 | -69,774,000 |
| Dec 2023 | 0 | -79,945,000 | -69,134,000 | 225,857,000 | 21,595,000 | 204,262,000 | -50,139,000 |
| Dec 2022 | 0 | -58,927,000 | -55,325,000 | 266,181,000 | 8,352,000 | 257,829,000 | -50,285,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-148,565,000
OpCashFlow TTM
—
Assets (Latest)
$383,362,000
Forward EPS
$-2.97
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANAB | ANAPTYSBIO, INC | $1.36B | $45.61 | — |
| NUVB | Nuvation Bio Inc. | $1.37B | $3.90 | — |
| OCUL | OCULAR THERAPEUTIX, INC | $1.32B | $6.02 | — |
| NBTX | Nanobiotix S.A. | $1.39B | $27.45 | — |
| MNKD | MANNKIND CORP | $1.31B | $4.07 | — |
News headlines (Yahoo Finance, 1h cache)
How Phase 2 Cancer Trial Data At Tyra Biosciences (TYRA) Has Changed Its Investment Story
2026-11-12 00:23 · Yahoo
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
2026-11-10 13:00 · Yahoo
Tyra Biosciences to Participate in Upcoming Investor Conferences
2026-11-05 21:05 · Yahoo
Tyra Biosciences (TYRA) Stock Looks Rich Against Its Book Value
2026-10-31 21:14 · Yahoo
Tyra Biosciences (TYRA) Stock Looks Expensive Against Its Book Value
2026-10-17 07:11 · Yahoo
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
2026-10-14 12:35 · Yahoo
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-09-14 10:45 · Yahoo
Tyra Plummets To 10-Month Low On Mixed Cancer Test; Why Analysts Are Upbeat
2026-09-09 20:54 · Yahoo
Tyra disappoints investors with bladder cancer data
2026-09-09 15:46 · Yahoo
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
2026-09-09 14:44 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.